Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Central retinal vein occlusion (CRVO) is a common cause of vision loss, typically affecting
individuals during the fifth through seventh decade of life. Eyes with severe CRVO have a
poor visual prognosis because current treatments address only secondary complications of CRVO
without treating its cause. Intra-ophthalmic artery injection of a small dose of t-PA (clot
busting medicine), also called intra-ophthalmic artery thrombolysis, may reopen the central
retinal vein-and address the cause of the disease- without exposing the subject to the risks
of systemic thrombolysis. Our project aims to evaluate the safety and efficacy of
intra-ophthalmic artery thrombolysis in subjects with CRVO.